avasimibe has been researched along with Hypercholesterolemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bocan, TM; Dagle, C; Krause, BR; Lathia, C; Lee, H; Lu, X; Major, T; Mueller, SB; Rosebury, WS | 1 |
| Brown, WV | 1 |
1 review(s) available for avasimibe and Hypercholesterolemia
| Article | Year |
|---|---|
Therapies on the horizon for cholesterol reduction.
Topics: Acetamides; Acetates; Anticholesteremic Agents; Azetidines; Carrier Proteins; Cholestyramine Resin; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxysteroid Dehydrogenases; Hypercholesterolemia; Membrane Glycoproteins; Pyrimidines; Rosuvastatin Calcium; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids | 2001 |
1 other study(ies) available for avasimibe and Hypercholesterolemia
| Article | Year |
|---|---|
The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits.
Topics: Acetamides; Acetates; Animals; Anticholesteremic Agents; Aorta, Thoracic; Arteriosclerosis; Base Sequence; Cholesterol; DNA Primers; Enzyme Inhibitors; Gene Expression; Humans; Hypercholesterolemia; Macrophages; Male; Matrix Metalloproteinases; Rabbits; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Tissue Inhibitor of Metalloproteinases | 2000 |